A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831

Mild cognitive impairment ("MCI") is defined as the "symptomatic pre‐dementia stage" on the continuum of cognitive decline. Currently, no medications have proven effective for MCI. Preclinical experiments indicate that NA‐831 is an endogenous small molecule that exhibits neuroprotection, neurogenesis, and cognitive protective properties across a range of disease models. NA‐831 has been shown to be safe and well tolerated in healthy volunteers. This study seeks to evaluate the efficacy and safety of NA‐83 in 126 subjects with mild cognitive impairment due to Alzheimer's Disease